Home » Stocks » OPK

OPKO Health, Inc. (OPK)

Stock Price: $4.13 USD 0.18 (4.56%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 2.77B
Revenue (ttm) 1.17B
Net Income (ttm) -114.06M
Shares Out 670.00M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 26.32
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $4.13
Previous Close $3.95
Change ($) 0.18
Change (%) 4.56%
Day's Open 3.98
Day's Range 3.95 - 4.15
Day's Volume 4,693,251
52-Week Range 1.12 - 6.47

More Stats

Market Cap 2.77B
Enterprise Value 3.00B
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 670.00M
Float 404.95M
EPS (basic) -0.18
EPS (diluted) -0.18
FCF / Share -0.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 130.22M
Short Ratio 12.90
Short % of Float 32.16%
Beta 1.93
PE Ratio n/a
Forward PE 26.32
P/FCF Ratio n/a
PS Ratio 2.38
PB Ratio 1.63
Revenue 1.17B
Operating Income -104.11M
Net Income -114.06M
Free Cash Flow -71.27M
Net Cash -232.91M
Net Cash / Share -0.35
Gross Margin 22.74%
Operating Margin -8.94%
Profit Margin -9.80%
FCF Margin -6.12%
ROA -0.60%
ROE -6.99%
ROIC -7.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
(93.70% upside)
Low
6.50
Current: $4.13
High
10.00
Target: 8.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9029909661,11749291.1396.5347.0427.9828.49
Revenue Growth-8.92%2.51%-13.56%127.25%439.63%-5.6%105.19%68.14%-1.81%-
Gross Profit32938634650625643.1247.6719.1710.7415.00
Operating Income-274-171-276-96.55-98.48-146-79.63-37.27-23.19-11.14
Net Income-315-153-305-48.36-30.03-172-114-29.05-1.28-18.93
Shares Outstanding595563559551488422355296281255
Earnings Per Share-0.53-0.27-0.55-0.10-0.06-0.41-0.32-0.11-0.01-0.08
Operating Cash Flow-173-109-92.0832.05164-90.38-55.65-25.42-18.50-18.71
Capital Expenditures-12.07-26.64-39.25-17.15-10.85-4.73-3.33-1.47-1.95-0.77
Free Cash Flow-185-136-13114.90153-95.11-58.98-26.89-20.45-19.49
Cash & Equivalents85.4596.4791.5016919496.9118627.3671.5218.02
Total Debt26194.7141.0955.6860.4514522417.538.7614.69
Net Cash / Debt-1751.7650.41113133-48.00-38.689.8462.763.33
Assets2,3092,4512,5902,7672,7991,2681,39229022977.85
Liabilities69566074667581943251986.5544.2228.67
Book Value1,6151,7911,8442,0921,98084287617916123.05
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OPKO Health, Inc.
Country United States
Employees 6,096
CEO Phillip Frost

Stock Information

Ticker Symbol OPK
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: OPK
IPO Date November 2, 1995

Description

OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.